What is claimed is:

1. Use of immunotherapeutic composition comprising

a) a yeast vehicle; and

b) a cancer antigen comprising at least one Brachyury antigen,

for the preparation of a medicament for reducing, arresting, reversing, delaying or preventing metastatic progression of cancer in an individual who has cancer, wherein the cancer is undergoing metastatic progression, is at risk of undergoing metastatic progression, or is predicted to begin undergoing metastatic progression, and wherein the Brachyury antigen comprises SEQ ID NO:18, positions 2-435 of SEQ ID NO:18, an amino acid sequence that is at least 85% identical to SEQ ID NO:18, SEQ ID NO:6, positions 2-435 of SEQ ID NO:6, an amino acid sequence that is at least 85% identical to SEQ ID NO:6, SEQ ID NO:2, positions 2-435 of SEQ ID NO:2, or an amino acid sequence that is at least 85% identical to SEQ ID NO:2.

2. The use according to claim 1, wherein Brachyury expression is not detected in the individual's cancer at the time the composition is first to be administered.

3. The use according to claim 2, wherein Brachyury expression is detected in the individual's cancer at the time the composition is first to be administered.

4. The use according to claim 1, wherein the individual has a pre-cancerous lesion.

5. The use according to claim 1, wherein the individual has cancer, but Brachyury-expressing cancer cells have not been detected in the cancer.

6. The use according to claim 1, wherein the individual has a stage I cancer, has stage II cancer, has stage III cancer or has stage IV cancer.

7. The use according to claim 1, wherein the individual is being treated or has been treated with another therapy for cancer.

8. The use according to claim 7, wherein the therapy is chemotherapy, targeted cancer therapy, radiation therapy, adoptive T cell transfer or surgical resection of a tumor from the individual.

9. The use according to claim 7, wherein the therapy is administration of one or more additional immunotherapeutic compositions.

10. The use according to claim 9, wherein the additional immunotherapeutic compositions comprise a yeast vehicle and a second cancer antigen that does not include Brachyury antigen.

11. The use according to claim 10, wherein the second cancer antigen is selected from the group consisting of: mutated Ras, carcinoembryonic antigen (CEA), MUC-1, EGFR, BCR-Abl, MART-1, MAGE-1, MAGE-3, GAGE, GP-100, MUC-2, PSMA, tyrosinase, TRP-1 (gp75), NY-ESO-1, TRP-2, TAG72, KSA, CA-125, PSA, HER-2/neu/c-erb/B2, hTERT, p73, B-RAF, adenomatous polyposis coli (APC), Myc, von Hippel-Lindau protein (VHL), Rb-1, Rb-2, androgen receptor (AR), Smad4, MDR1, Flt-3, BRCA-1, BRCA-2, pax3-fkhr, ews-fli-1, HERV-H, HERV-K, TWIST, Mesothelin, and NGEP.

12. The use according to any one of claims 1 to 11, wherein the cancer is selected from the group consisting of: breast cancer, small intestine cancer, stomach cancer, pancreatic cancer, kidney cancer, bladder cancer, uterine cancer, ovarian cancer, testicular cancer, lung cancer, colon cancer, prostate cancer, chronic lymphocytic leukemia (CLL), Epstein-Barr virus transformed B cells, Burkitt's lymphoma, Hodgkin's lymphoma, and metastatic cancers thereof.

13. The use according to any one of claims 1 to 12, wherein the Brachyury antigen has an amino acid sequence represented by SEQ ID NO:18, SEQ ID NO:6, or SEQ ID NO:2, or an amino acid sequence that is at least 85% identical to SEQ ID NO:18, SEQ ID NO:6, or SEQ ID NO:2.

14. The use according to any one of claims 1 to 12, wherein the Brachyury antigen has an amino acid sequence represented by SEQ ID NO:18, SEQ ID NO:6, or SEQ ID NO:2, or an amino acid sequence that is at least 90% identical to SEQ ID NO:18, SEQ ID NO:6, or SEQ ID NO:2.

15. The use according to any one of claims 1 to 12, wherein the Brachyury antigen has an amino acid sequence represented by SEQ ID NO:18, SEQ ID NO:6, or SEQ ID NO:2, or an amino acid sequence that is at least 95% identical to SEQ ID NO:18, SEQ ID NO:6, or SEQ ID NO:2.

16. The use according to any one of claims 1 to 15, wherein the Brachyury antigen comprises positions 246 to 254 of SEQ ID NO:18, SEQ ID NO:6, or SEQ ID NO:2.

17. The use according to any one of claims 1 to 15, wherein the Brachyury antigen comprises positions 246 to 254 of SEQ ID NO:18.

18. The use according to any one of claims 1 to 15, wherein the Brachyury antigen comprises a substitution of a leucine at position 254 with a valine of SEQ ID NO:18.

19. The use according to any one of claims 1 to 12, wherein the Brachyury antigen comprises an amino acid sequence that is at least 99% identical to SEQ ID NO:18, at least 99% identical to SEQ ID NO:6, or at least 99% identical to SEQ ID NO:2.

20. The use according to claims 1 to 19, wherein the cancer antigen is a fusion protein having an amino acid sequence represented by SEQ ID NO:8, SEQ ID NO:20 or an amino acid sequence that is at least 95% identical to SEQ ID NO:8 or SEQ ID NO:20.

21. The use according to claim 20, wherein expression of the fusion protein is under the control of the promoter *CUP1*.

22. The use according to any one of claims 1 to 21, wherein the yeast vehicle is a killed whole yeast.

23. The use according to claim 21, wherein the whole yeast is heat-inactivated.

24. The use according to any one of claims 1 to 23, wherein the yeast vehicle expresses the antigen.

25. The use according to any one of claims 1 to 24, wherein the yeast is from *Saccharomyces cerevisiae*.

26. The use according to any one of claims 1 to 24, wherein the composition is formulated in a pharmaceutically acceptable excipient suitable for administration to a subject.

27. Use of the immunotherapeutic composition of claim 1 and a first immunotherapeutic composition comprising a yeast vehicle and a first cancer antigen that does not comprise a Brachyury antigen in the preparation of a medicament for treating cancer wherein, the first immunotherapeutic composition is to be administered to an individual, prior to, concurrently with, sequentially with, or subsequent to, the immunotherapeutic composition of claim 1.

28. The use according to claim 27, further comprising one or more additional immunotherapeutic compositions to be administered, wherein the each of the one or more additional immunotherapeutic compositions comprises an additional cancer antigen.

29. Use of immunotherapeutic composition comprising

a) a whole, inactivated yeast; and

b) a Brachyury fusion protein comprising the amino acid sequence of positions 2-435 of SEQ ID NO:6 or the amino acid sequence of positions 2-435 of SEQ ID NO:18;

wherein the Brachyury fusion protein is expressed by the yeast; and wherein the composition elicits a Brachyury-specific T cell response, for the preparation of a medicament for treating a disease or condition associated with Brachyury expression.

30. Use of an immunotherapeutic composition comprising:

c) a whole, inactivated yeast; and

d) a Brachyury fusion protein comprising the amino acid sequence of positions 2-435 of SEQ ID NO:6 or the amino acid sequence of positions 2-435 of SEQ ID NO:18;

wherein the Brachyury fusion protein is expressed by the yeast; and wherein the composition elicits a Brachyury-specific T cell response, in the preparation of a medicament for reducing tumor burden in an individual, increasing survival of an individual, and/or inhibiting tumor growth in an individual.

31. The use according to Claim 30, wherein the tumor is of epithelial cell origin.

32. The use according to Claim 30, wherein the individual has a cancer selected from the group consisting of: breast cancer, small intestine cancer, stomach cancer, pancreatic cancer, kidney cancer, bladder cancer, uterine cancer, ovarian cancer, testicular cancer, lung cancer, colon cancer, prostate cancer, chronic lymphocytic leukemia (CLL), Epstein-Barr virus transformed B cells, Burkitt's lymphoma, Hodgkin's lymphoma, and metastatic cancers thereof.

33. The use according to Claim 30, wherein the individual is being treated or has been treated with another therapy for cancer.

34. The use according to Claim 30 further comprising one or more additional immunotherapeutic compositions to be administered, wherein the each of the one or more additional immunotherapeutic compositions comprises an additional cancer antigen.

35. The use according to Claim 33, wherein the therapy is chemotherapy.

36. The use according to Claim 33, wherein the therapy is targeted cancer therapy.

37. The use according to Claim 33, wherein the therapy is radiation therapy.

38. The use according to Claim 33, wherein the therapy is adoptive T cell transfer.

39. The use according to Claim 33, wherein the therapy is administration of one or more additional immunotherapeutic compositions.

40. The use according to Claim 39, wherein the additional immunotherapeutic compositions comprise a yeast vehicle and a second cancer antigen that does not include Brachyury antigen.

41. The use according to Claim 40, wherein the second cancer antigen is selected from the group consisting of: mutated Ras, carcinoembryonic antigen (CEA), MUC-1, EGFR, BCR-Abl, MART-1, MAGE-1, MAGE-3, GAGE, GP-100, MUC-2, PSMA, tyrosinase, TRP-1 (gp75), NY-ESO-1, TRP-2, TAG72, KSA, CA-125, PSA, HER-2/neu/c-erb/B2, hTERT, p73, B-RAF, adenomatous polyposis coli (APC), Myc, von Hippel-Lindau protein (VHL), Rb-1, Rb-2, androgen receptor (AR), Smad4, MDR1, Flt-3, BRCA-1, BRCA-2, pax3-fkhr, ews-fli-1, HERV-H, HERV-K, TWIST, Mesothelin, and NGEP.

42. The use according to Claim 41, wherein the second cancer antigen is selected from the group consisting of: mutated Ras, carcinoembryonic antigen (CEA), and MUC-1.

43. The use according to Claim 30 wherein the Brachyury fusion protein comprises the amino acid sequence of positions 2-435 of SEQ ID NO:6.

44. The use according to Claim 30 wherein the Brachyury fusion protein comprises the amino acid sequence of positions 2-435 of SEQ ID NO:18.

45. The use according to Claim 30 wherein the Brachyury fusion protein comprises the amino acid sequence of SEQ ID NO:8.

46. The use according to Claim 30 wherein the Brachyury fusion protein comprises the amino acid sequence of SEQ ID NO:20.

47. The use according to Claim 30, wherein the whole yeast is heat-inactivated.

48. The use according to Claim 30, wherein the yeast is *Saccharomyces cerevisiae*.

49. An immunotherapeutic composition comprising:

a) a yeast vehicle;

b) a cancer antigen comprising a Brachyury antigen, wherein the Brachyury antigen comprises SEQ ID NO:6, positions 2-435 of SEQ ID NO:6, SEQ ID NO:18, positions 2-435 of SEQ ID NO:18, or an amino acid sequence that is at least 85% identical to SEQ ID NO:18 and comprises a substitution of a leucine at position 254 with a valine; and

c) a pharmaceutically acceptable excipient suitable for administration to a human.

50. The immunotherapeutic composition of Claim 49, wherein the Brachyury antigen comprises an amino acid sequence that is at least 90% identical to SEQ ID NO:18 and comprises a substitution of a leucine at position 254 with a valine.

51. The immunotherapeutic composition of Claim 49, wherein the Brachyury antigen comprises an amino acid sequence that is at least 95% identical to SEQ ID NO:18 and comprises a substitution of a leucine at position 254 with a valine.

52. The immunotherapeutic composition of Claim 49, wherein the yeast vehicle is a whole yeast.

53. The immunotherapeutic composition of Claim 52, wherein the whole yeast is killed.

54. The immunotherapeutic composition of Claim 53, wherein the whole yeast is heat-inactivated.

55. The immunotherapeutic composition of Claim 49, wherein the yeast vehicle expresses the antigen.

56. The immunotherapeutic composition of Claim 49, wherein the yeast is from a genus selected from the group consisting of: *Saccharomyces, Candida, Cryptococcus, Hansenula, Kluyveromyces, Pichia, Rhodotorula, Schizosaccharomyces* and *Yarrowia*.

57. The immunotherapeutic composition of Claim 49, wherein the yeast is from *Saccharomyces*.

58. The immunotherapeutic composition of Claim 49, wherein the yeast is from *Saccharomyces cerevisiae*.